Cellular Basis for the Antifungal Activity of Amiodarone
胺碘酮抗真菌活性的细胞基础
基本信息
- 批准号:7879726
- 负责人:
- 金额:$ 3.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-14 至 2011-09-30
- 项目状态:已结题
- 来源:
- 关键词:AmiodaroneAmphotericin BAnabolismAnimal ModelAnti-Arrhythmia AgentsAntifungal AgentsAntioxidantsApoptosisApoptoticAppearanceAspergillusAspergillus fumigatusAtrial FibrillationBiochemicalBiochemical GeneticsBiologicalBiological AssayCalcineurinCalciumCandidaCandida albicansCaspaseCaspase InhibitorCaspofunginCell DeathCell membraneCellsChelating AgentsChemicalsCollectionCombined Modality TherapyCryptococcusCryptococcus neoformansDNA Microarray ChipDataDatabasesDefectDevelopmentDisseminated candidiasisDoseDrug Delivery SystemsDrug DesignDrug resistanceDrug toxicityDrug usageErgosterolEventExhibitsFluconazoleFungal Drug ResistanceGenerationsGenesGoalsGrowthHomeostasisHypersensitivityIn VitroIndustrial fungicideInterventionIon ChannelItraconazoleKnock-outLeadLibrariesLinkMediatingMiconazoleMicroarray AnalysisMitochondriaModelingMolecularMolecular ProfilingMusMutationMycosesPathway interactionsPharmaceutical PreparationsProteinsReactive Oxygen SpeciesResearch PersonnelResistanceReverse Transcriptase Polymerase Chain ReactionSaccharomycesSaccharomyces cerevisiaeSaccharomycetalesSerineSignal PathwaySignaling Pathway GeneTestingTimeToxic effectVacuoleVentricular ArrhythmiaWorkYeastsanalogbasecytochrome cdronedaronedrug discoveryfungusgenome-widein vivoinhibitor/antagonistknockout genemitochondrial membranemutantnovelpathogenprogramspublic health relevanceresearch studyresponsesynergismtraffickingweapons
项目摘要
The goal of this proposal is to elucidate the pathway of programmed cell death by a novel antifungal agent
and explore its use as an antimycotic adjunct. Amiodarone is an effective antiarrhythmic drug that was
recently discovered to have potent and broad range fungicidal activity. We have shown that amiodarone
toxicity in the yeast Saccharomyces cerevisiae is mediated by disruption of calcium homeostasis, followed
by the appearance of apoptosis markers and cell death. In Aim 1, we propose to use a combination of
biochemical and cell biological approaches to determine the identity and temporal order of events leading
from the initial burst of cytosolic calcium to cell death. We will seek to validate key findings in the pathogenic
yeast Candida albicans as proof-of-principle for the universality of the fungicidal mechanism of amiodarone.
In Aim 2, we will use a variety of genome-wide approaches to identify the genes and signaling pathways that
contribute to amiodarone-induced cell death. Genes identified by these studies will be organized into
biomodules and placed in cellular pathways by integrating experimental data from high-throughput
biochemical assays with information from online databases to give a global view of drug toxicity. We have
shown that low doses of amiodarone exhibit potent synergism with existing antifungals against pathogenic
fungal species of Candida, Cryptococcus and Aspergillus. Drug synergy from these in vitro studies will form
the basis for combination therapy that will be explored in a murine model of systemic Candidiasis (Aim3).
Taken together these studies will develop the calcium-mediated cell death pathway as a major new drug
discovery target opportunity. Amiodarone will serve as a model test compound for targeting this pathway and
for validating the potential of a new class of antifungal potentiating agents.
The public health relevance of this project arises from the emergence of new fungal pathogens and drug
resistant fungi, and the urgent need for alternative strategies in the management of fungal infections.
本提案的目的是阐明一种新型抗真菌药物引起的细胞程序性死亡的途径
并探索其作为抗真菌辅助剂的用途。胺碘酮是一种有效的抗心律失常药物,
最近发现具有有效和广泛的杀真菌活性。我们已经证明胺碘酮
在酿酒酵母中的毒性是通过破坏钙稳态介导的,
凋亡标记物和细胞死亡的出现。在目标1中,我们建议使用以下组合:
生物化学和细胞生物学方法,以确定事件的身份和时间顺序,
从胞质钙离子的初始爆发到细胞死亡。我们将寻求验证致病性的关键发现,
酵母菌白色念珠菌作为胺碘酮杀真菌机制普遍性的原理证明。
在目标2中,我们将使用各种全基因组方法来识别基因和信号通路,
有助于胺碘酮诱导的细胞死亡。这些研究所确定的基因将被组织成
生物模块,并通过整合来自高通量的实验数据,
利用在线数据库中的信息进行生物化学测定,以提供药物毒性的全局视图。我们有
表明低剂量胺碘酮与现有抗真菌药对病原体
念珠菌属、隐球菌属和曲霉属的真菌种类。这些体外研究的药物协同作用将形成
联合治疗的基础将在系统性疟原虫病的鼠模型中探索(Aim3)。
综合这些研究将开发钙介导的细胞死亡途径作为一个主要的新药
发现目标的机会胺碘酮将作为靶向该途径的模型试验化合物,
用于验证一类新的抗真菌增效剂的潜力。
该项目的公共卫生相关性源于新的真菌病原体和药物的出现。
耐药真菌,并迫切需要在真菌感染的管理替代策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RAJINI RAO其他文献
RAJINI RAO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RAJINI RAO', 18)}}的其他基金
Training Program In Cellular and Molecular Medicine
细胞和分子医学培训计划
- 批准号:
10197161 - 财政年份:2020
- 资助金额:
$ 3.28万 - 项目类别:
Training Program In Cellular and Molecular Medicine
细胞和分子医学培训计划
- 批准号:
10439771 - 财政年份:2020
- 资助金额:
$ 3.28万 - 项目类别:
Training Program In Cellular and Molecular Medicine
细胞和分子医学培训计划
- 批准号:
10650362 - 财政年份:2020
- 资助金额:
$ 3.28万 - 项目类别:
2016 Membrane Transport Proteins: Translating Molecules to Medicine Gordon Research Conference and Seminar
2016膜转运蛋白:将分子转化为药物戈登研究会议及研讨会
- 批准号:
9193325 - 财政年份:2016
- 资助金额:
$ 3.28万 - 项目类别:
Transport Mechanism and Renal Function of a Newly Recognized Na+/H+ Exchanger
新认识的Na /H交换剂的转运机制和肾功能
- 批准号:
9148249 - 财政年份:2015
- 资助金额:
$ 3.28万 - 项目类别:
Transport Mechanism and Renal Function of a Newly Recognized Na+/H+ Exchanger
新认识的Na /H交换剂的转运机制和肾功能
- 批准号:
9339660 - 财政年份:2015
- 资助金额:
$ 3.28万 - 项目类别:
Endosomal Na+/H+ Exchangers From Yeast and Human: Role and Regulation
酵母和人类内体 Na /H 交换器:作用和调节
- 批准号:
7463033 - 财政年份:2008
- 资助金额:
$ 3.28万 - 项目类别:
Endosomal Na+/H+ Exchangers From Yeast and Human: Role and Regulation
酵母和人类内体 Na /H 交换器:作用和调节
- 批准号:
8091274 - 财政年份:2008
- 资助金额:
$ 3.28万 - 项目类别:
相似海外基金
有機分子触媒を用いたAmphotericin Bの合成研究
有机分子催化剂合成两性霉素B的研究
- 批准号:
24K17671 - 财政年份:2024
- 资助金额:
$ 3.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EnLAmB - Enabling global access to affordable generic liposomal amphotericin B injectable formulations via advanced manufacturing technology
EnLAmB - 通过先进的制造技术,使全球能够获得负担得起的通用脂质体两性霉素 B 注射制剂
- 批准号:
MR/X014010/1 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
Research Grant
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
- 批准号:
559052-2021 - 财政年份:2022
- 资助金额:
$ 3.28万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Study on naturally-occurring peptides potentiating amphotericin B activity
天然存在的肽增强两性霉素 B 活性的研究
- 批准号:
22K05333 - 财政年份:2022
- 资助金额:
$ 3.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
- 批准号:
559052-2021 - 财政年份:2021
- 资助金额:
$ 3.28万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
- 批准号:
10024667 - 财政年份:2020
- 资助金额:
$ 3.28万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
9909193 - 财政年份:2020
- 资助金额:
$ 3.28万 - 项目类别:
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
- 批准号:
10248529 - 财政年份:2020
- 资助金额:
$ 3.28万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
10484014 - 财政年份:2020
- 资助金额:
$ 3.28万 - 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
- 批准号:
10654834 - 财政年份:2020
- 资助金额:
$ 3.28万 - 项目类别: